Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Efficacy of Olipudase Alfa in ASMD
NCT02004704Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2013
- Primary completion
- Sep 2023
- Modality
- Replacement Enzymes
- Countries
- 7
01
Overview
A Phase 2 trial of olipudase alfa in acid sphingomyelinase deficiency (ASMD), sponsored by Sanofi. Started Dec 2013; status: completed.
02
Drugs
olipudase alfa
03
Conditions
acid sphingomyelinase deficiency (ASMD)
Beyond the preview
Go deeper on NCT02004704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02004704.